NutraCast Podcast: Attorney Durkin on the 'Race to Market'

This content item was originally published on, a William Reed online publication.

By Danielle Masterson contact

- Last updated on GMT

NutraCast Podcast: Attorney Durkin on the 'Race to Market'

Related tags: nutracast, NAC, Cbd, race to market, fdca

Attorney Bob Durkin said that he regularly comes across clients who are curious about the prospects of studying an ingredient for use in both food and drugs.

That’s when he has to let them know that studying an ingredient as a drug may preclude it from being lawfully included in a food or product labeled as a “dietary supplement” under the Food, Drug, and Cosmetics Act (the “Act”).

However, Durkin said companies shouldn’t necessarily avoid doing it altogether.  “What they should do is make sure they do things in the right order. There are two separate provisions of the ACT Sections 301(ll) and 201(ff)(3B), that taken together, work to exclude from being added to food or from the definition of a dietary supplement, an article that was either an approved drug or studied in certain ways to be an approved drug before it was introduced in the commerce as a food or a dietary supplement. So it's not that interested folks out there shouldn't explore the monetization opportunities of an ingredient, they just need to be careful that they do it in a way that doesn't exclude all the possibilities of that monetization.”

The two sections of the Act have come to be known in the industry as creating a “race to market” between those interested in investigating an article as a drug and others interested in marketing the same article as a food, including food labeled as dietary supplements. 

Durkin said the FDA is relying on these sections of the Act in its current determination that CBD is a violative ingredient.

“It's almost as though the use of the Epidiolex IND to exclude CBD from being a food or dietary supplement may have gained a little more little more traction than it should have and I think it might be being relied on now to exclude other naturally derived extracts that contains CBD from being included in a food or a dietary supplement. That seems like it might be an overly broad application of the statute by the agency,”​ observed Durkin. 

To hear more about the ‘race to market’, and how CBD and NAC, another ingredient that has had similar issues, come into play, listen to the NutraCast. You can also subscribe on iTunes​, Spotify ​, Stitcher​ and Google Podcasts​. 

NutraCast is a podcast that focuses on insights from inside the nutrition industry. It is a production by NutraIngredients-USA. Music by Kevin Macleod.

Related news

Related products

show more

Plant-based Proteins Collection from Ingredients4U

Plant-based Proteins Collection from Ingredients4U

Ingredients4u AG | 27-Sep-2021 | Technical / White Paper

Plant-based products have always been a hot topic in the market, the plant-based food market was valued at $29.4 billion in 2020. Ingredients4U is one...

Reach Consumers with Fruit & Vegetable Powders

Reach Consumers with Fruit & Vegetable Powders

vaneeghen | 08-Sep-2021 | Technical / White Paper

Are you looking to create products that appeal to today’s plant-forward consumers? The plant-based revolution continues to captivate the market as consumers...

Turmacin®: Clean Label & Clinically Tested Turmeric

Turmacin®: Clean Label & Clinically Tested Turmeric

Natural Remedies Private Limited | 01-Sep-2021 | Product Presentation

Turmacin® is a clean label project-certified, clinically tested, and clinically safe turmeric extract. Turmacin® is rich in Turmerosaccharides® and doesn't...

Related suppliers

Follow us


View more